Key takeaways
Zeposia (ozanimod) and Ocrevus (ocrelizumab) are both medications used to treat multiple sclerosis (MS). However, they belong to different medication classes and have distinct uses and administration methods. Zeposia is a sphingosine 1-phosphate receptor modulator taken orally, while Ocrevus is a monoclonal antibody given as an infusion. Zeposia is also approved for treating moderate-to-severe ulcerative colitis (UC), whereas Ocrevus is the only FDA-approved medication for primary progressive MS. Zeposia is taken daily, with a starter pack to gradually increase the dose, while Ocrevus is administered every six months after initial doses. Common side effects of Zeposia include upper respiratory infections and liver enzyme changes, while Ocrevus can cause infusion reactions and upper respiratory tract infections. Both medications can increase the risk of infections. Rarely, Ocrevus may increase your risk of some types of cancers.
